Cancer, a heterogeneous group of diseases, has long been understood to have a genetic basis, though the precise mechanisms remained elusive until the advent of molecular biology.  Early research focused on identifying oncogenes and tumor suppressor genes, revealing the pivotal role of somatic mutations in uncontrolled cell proliferation.  This foundational knowledge facilitated the development of targeted therapies, initially focusing on broad classes of mutations, like EGFR inhibitors for lung cancer.  However, the inherent inter- and intra-tumor heterogeneity underscored the limitations of this "one-size-fits-all" approach.

Recent advances in next-generation sequencing (NGS) and bioinformatics have propelled the field of personalized oncology.  Comprehensive genomic profiling allows for the identification of driver mutations specific to an individual's tumor, enabling the selection of tailored therapies.  This precision medicine approach, encompassing pharmacogenomics and immunotherapies informed by tumor mutational burden, significantly improves treatment efficacy and minimizes adverse effects.  Ongoing research focuses on integrating multi-omics data (genomics, transcriptomics, proteomics) to refine predictive biomarkers and develop novel therapeutic strategies, ultimately striving for truly individualized cancer management.  Challenges remain in addressing the cost and accessibility of these advanced technologies, but the paradigm shift towards personalized approaches promises to revolutionize cancer treatment outcomes.